Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

NCT05167513 is registered in ClinicalTrials.gov with Getz Pharma as lead sponsor.

NCT NCT05167513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05167513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
Lead sponsor
Getz Pharma
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2021
Completion date
April 28, 2022
Enrollment
188 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metformin+sitagliptin, quality of life, type 2 diabetes